For adults with Chronic Idiopathic Constipation (CIC)

Once daily. Anytime.
With or without food.

Select Important Safety Information

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Once-daily dosing

Motegrity offers simple dosing to work with your patients’ schedule.1

Dosing icon

Once-daily dosing

Wrist watch

Any time of the day

Fork, spoon and knife

With or without food

It is important for patients to understand that Motegrity must be taken once daily as prescribed.1

Two dosage strengths

2 mg

  • Recommended once daily adult CIC dosage1

1 mg

  • Recommended once daily dosage for CIC patients with severe renal impairment (creatinine clearance <30 mL‍/‍min)1
  • Avoid Motegrity in patients with end-stage renal disease requiring dialysis1

Storing Motegrity properly

Tablets Bottle

Storing Motegrity properly

Advise patients to:

  • Store Motegrity at 68°F to 77°F; with excursions permitted between 59°F to 86°F1
  • Store Motegrity in the original container to protect from moisture1

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for persistent worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if their depression is persistently worse, or they experience emerging suicidal thoughts or behaviors.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

Indication

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

Reference:

1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Shire LLC.